0
0
0
0
1
2
3
$0
Is XPeng solid or fragile? The Finex Financial Health Scanner reads XPEV's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $11.0B |
|---|---|
| Net income | -$163.1M |
| Operating margin | -3.6% |
| Net margin | -1.5% |
| Cash and investments | $3.9B |
| Total debt | $4.7B |
| Free cash flow | $730.2M |
| Revenue growth (1 year) | 96.1% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.